Cerebrospinal Fluid Testing of Alzheimer's Patients to Help Identify Disease Molecular Subtype

Scientists have made a significant discovery by identifying five distinct biological variants of Alzheimer's disease, each potentially requiring unique therapeutic approaches. This finding suggests that drugs previously tested for Alzheimer's might have been wrongly deemed ineffective or only slightly beneficial due to these variants being unaccounted for.

At the core of Alzheimer's disease is the accumulation of amyloid and tau proteins in the brain. However, this aggregation is just one aspect of the disease's complexity. Researchers, including those from Amsterdam UMC (Amsterdam, Netherlands), have employed innovative methods to analyze additional biological processes involved in Alzheimer's. These processes, which include inflammation and the growth of nerve cells, were studied through the measurement of various biomarkers in the cerebrospinal fluid of patients exhibiting amyloid and tau accumulations. In their analysis of the cerebrospinal fluid of 419 individuals diagnosed with Alzheimer's, the researchers assessed 1,058 proteins and identified five distinct biological subtypes within the disease. The first subtype is marked by heightened amyloid production, while the second shows a disrupted blood-brain barrier, diminished amyloid production, and reduced neural growth.

These subtypes also exhibit variations in protein synthesis, immune system functionality, and the performance of the organ responsible for cerebrospinal fluid production. Distinct subgroups within these variants were observed to have differing disease progression rates. This discovery holds significant implications for Alzheimer's drug research. A drug effective for one Alzheimer's subtype may not be suitable for another. For instance, a medication designed to reduce amyloid production could be beneficial for patients with increased amyloid production but detrimental to those with reduced levels. There is also the possibility that patients with a certain Alzheimer's variant may experience more side effects compared to those with other variants. The researchers' next goal is to demonstrate that these Alzheimer's subtypes indeed respond differently to medications. This would pave the way for more personalized and effective treatments for Alzheimer's disease in the future.

Related Links:
Amsterdam UMC

Visit expo >

Gold Member

Pharmacogenetics Panel

VeriDose Core Panel v2.0

Verification Panels for Assay Development & QC
Seroconversion Panels

New

Hemoglobin/Haptoglobin Assay

IDK Hemoglobin/Haptoglobin Complex ELISA

New

Benchtop Cooler

PCR-Cooler & PCR-Rack